Pfizer and BioNTech seek full approval for Covid-19 vaccine in the US
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Pfizer and BioNTech seek full approval for Covid-19 vaccine in the US

10 May 2021 (Last Updated May 10th, 2021 12:26)

Pfizer and BioNTech have begun the rolling submission of a Biologics License Application (BLA) to obtain full approval from the US Food and Drug Administration (FDA) for their Covid-19 vaccine in individuals aged 16 years and above. 

Pfizer and BioNTech seek full approval for Covid-19 vaccine in the US
So far, over 170 million doses of the vaccine have been distributed in the US. Credit: x3 / Pixabay.

This Pfizer and BioNTech mRNA vaccine received an Emergency Use Authorization (EUA) from the FDA in December last year. So far, over 170 million doses of the vaccine have been distributed in the country.

The BLA submission is an FDA review process that needs longer-term follow-up data for acceptance and approval.

The companies said they have begun the BLA submission by providing the nonclinical and clinical data, including the latest analyses from a Phase III clinical trial.

In the Phase III trial, the vaccine was effective with a favourable safety profile for up to six months following the second dose.

Pfizer and BioNTech will also submit the manufacturing and facility data needed for the BLA soon.

Recently, the companies sought expanded EUA for the Covid-19 vaccine to include people aged between 12 and 15 years. A supplemental BLA will be submitted to support approval in this age group after obtaining the six months data following the second vaccine dose.

Pfizer chairman and CEO Albert Bourla said: “We look forward to working with the FDA to complete this rolling submission and support their review, with the goal of securing full regulatory approval of the vaccine in the coming months.”

Last week, Health Canada expanded the interim order (IO) authorisation for Pfizer and BioNTech’s Covid-19 vaccine to include adolescents aged 12 to 15 years.

In another development, the European Medicines Agency (EMA) has commenced a rolling review of data on GlaxoSmithKline (GSK) and Vir Biotechnology’s sotrovimab (previously VIR-7831) for treating adults and adolescents aged 12 years and above with Covid-19.

An investigational dual-action SARS-CoV-2 monoclonal antibody, sotrovimab is intended for Covid-19 patients who do not need supplemental oxygen and are at risk of progression to severe disease.